BRC News

A trial of a new version of the AstraZeneca vaccine is to start at UCLH to see if it is effective against the Covid-19 variant first identified in South Africa.

A UCL team want to hear from researchers across the UK about their experience of involving patients and the public in rapid qualitative research.

A UCL report published today sets out a new framework and recommendations on how to reduce health inequities across the UK and ‘build back fairer’ following the pandemic.

Two doses of the Oxford-AstraZeneca COVID-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains.

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to research in which UCLH played a key role.

A UCLH team that developed a live bed management tool during the Covid surge in London have been named finalists for a national health data award.

UCLH and UCL are part of an international consortium awarded a substantial prize to further develop an innovative infectious disease outbreak detection system.

More than nine in ten patients taking part in research at UCLH would consider doing so again and felt valued for their participation, according to a national survey.

Presence of tumour DNA in the blood – a biomarker or indicator of disease first identified by a BRC-supported consortium – can predict which cancer patients are most likely to relapse after having a tumour surgically removed and most likely to benefit from immunotherapy.

Pioneering technology developed by UCL and Africa Health Research Institute (AHRI) could transform the ability to accurately interpret HIV test results.

Members of the public joined an interactive workshop to find out how health data is collected and can be used in research to improve patient care.

UCLH and UCL clinicians and researchers have been recognised in the Queen’s Birthday Honours 2021.

UCL has been ranked highly in leading international university league tables including eighth globally in the 2022 World University Rankings.

Researchers at the NIHR UCLH Clinical Research Facility are the first in the world to start a new first-in-human trial investigating a novel treatment, called NVG-111, in patients with Non-Hodgkin lymphoma (NHL) subtypes, including relapsed/refractory chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL).

Read the first edition of the NIHR UCLH Clinical Research Facility’s (CRF) early phase cancer trials newsletter.